Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
The failure of a crucial pivotal study consigns Blueprint’s lead drug, Ayvakit, to a tiny niche.
In the battle between two Kit/PDGFRα kinase inhibitors first blood goes to Blueprint’s avapritinib.
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
Positive data should pave the way for ripretinib’s approval in fourth-line GIST, but investors are already eyeing a bigger opportunity.
The small-molecule oncology player zeroes in on its first commercial opportunity.
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.